Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Presentation of benefits and harms of antidepressants on websites: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Breast Cancer Screening and Diagnosis

    Research output: Contribution to journalLetterpeer-review

  2. Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review

    Research output: Contribution to journalReviewpeer-review

  3. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Selective reporting of trial results is common.

OBJECTIVE: To study selective reporting in clinical study reports, company trial registers and publications of quality of life in placebo-controlled trials of antidepressants.

METHODS: We compared clinical study reports of four antidepressants (fluoxetine, duloxetine, paroxetine and sertraline) obtained from two European drug regulators, data from online company registers, and publications received or retrieved from Eli Lilly and GlaxoSmithKline. Pfizer was also contacted but did not provide any publications.

RESULTS: We included 15 trials (19,015 pages) and 4717 patients. Six trials had used SF-36, seven EQ-5D and two both instruments. Nine of the 15 CSRs (60%) displayed selective reporting. In the companies' online registers, there was selective reporting for all 15 trials (100%). We received 20 publications from Eli Lilly and retrieved six from the GlaxoSmithKline register. There was selective reporting in 24 of the 26 publications (92%). Despite extensive selective reporting, we found only small differences between placebo and active drugs.

CONCLUSIONS: Access to the full raw data from clinical trials and to case report forms for all patients are needed to evaluate the effect of antidepressants on quality of life. Regulatory agencies should refuse to approve drugs or new indications based on incomplete reporting.

Original languageEnglish
JournalInternational Journal of Risk and Safety in Medicine
ISSN0924-6479
DOIs
Publication statusPublished - 1 Oct 2020

ID: 61351942